Clinical trial
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Minocin IV for the Treatment of Infections Presumed or Confirmed to be Caused by Gram-negative Bacteria in a Real World Setting
NCT03160040 is registered in ClinicalTrials.gov with Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Minocin IV for the Treatment of Infections Presumed or Confirmed to be Caused by Gram-negative Bacteria in a Real World Setting
- Lead sponsor
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
- Phase
- Observational
- Overall status
- Completed
- Start date
- October 11, 2017
- Completion date
- May 1, 2018
- Enrollment
- 71 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.